机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[2]Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院[3]Department of Radiation Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, Sichuan, China四川大学华西医院
This research was funded by Youth Project of Sichuan Natural
Science Foundation (No. 2023NSFSC1892).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区医学
小类|3 区外科
最新[2025]版：
大类|3 区医学
小类|3 区外科
第一作者：
第一作者机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China[2]Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Thoracic Surgery, West China Hospital, Sichuan University, Chengdu, Sichuan, China[2]Lung Cancer Center & Institute, West China Hospital, Sichuan University, Chengdu, Sichuan, China
推荐引用方式(GB/T 7714)：
Liu Zhenkun,Huang Kaili,Wu Qiang,et al.Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma[J].Asian Journal Of Surgery.2023,doi:10.1016/j.asjsur.2023.11.152.
APA：
Liu Zhenkun,Huang Kaili,Wu Qiang&Zhou Qinghua.(2023).Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma.Asian Journal Of Surgery,,
MLA：
Liu Zhenkun,et al."Coexistence of a novel intergenic (between CHST2 and SLC9A9)-ALK, TNIK-ALK double-fusion in resected lung adenocarcinoma".Asian Journal Of Surgery .(2023)
